"Biogen is by far the worst-performing large-cap biotech stock of 2019 after the March failure of its key Alzheimer’s drug pushed its shares down more than 20 percent. Its first-quarter earnings results announced on Wednesday, while beating analysts’ profit estimates, did little to turn things around. A much-needed strategic shift was missing."
Posts published in “Business”
"The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange."
"Biogen Inc. BIIB announced two strategic collaborations to develop potential therapies for Alzheimer's disease, Parkinson's disease and other devastating neurological diseases."
"AC Immune and Lilly’s partnership will combine AC Immune’s proprietary Morphomer platform technology with Lilly’s commercial and clinical development capabilities. The collaboration with focus on AC’s lead molecule ACI-3024, which demonstrated tau aggregation inhibition in preclinical models."
"BioXcel Therapeutics Inc. ( BTAI ) announced proof-of-concept data from its Phase 1 study of IV (intravenous) dexmedetomidine or Dex for acute treatment of agitation in patients with Senile Dementia of the Alzheimer's Type or SDAT"
"Through a combination of assessments, screeners, workflows and clinical decision support algorithms, BrainCheck Care enables physicians to provide a detailed, personalized care plan to the patient and caregiver at the point of care."
"Since releasing initial BAN2401 results in July, excitement among investors has waned as detailed analysis has shown confounding results. However, many investors still see promise in the drug."
"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration combines AC Immune’s proprietary MorphomerTM platform technology with Lilly’s clinical development expertise and commercial capabilities in central nervous system disorders. The collaboration will focus primarily on AC Immune’s lead molecule, ACI-3024, which has demonstrated tau aggregation inhibition in preclinical models."
"InvestAcure, PBC, a Common Need Investment firm for Alzheimer's R&D, announced today that David Weild IV, Former Vice Chairman of the NASDAQ, frequently referred to as "The Father of the JOBS Act," will join the company as Co-founder & Vice Chairman of its board of directors."
"Axovant Sciences' ( AXON ) investigational drug Nelotanserin for the treatment of REM sleep behavior disorder in patients with Lewy body dementia has failed in a phase II trial, sending the shares down over 27%."